Viral Evolution in Response to the Broad-Based Retroviral Protease Inhibitor TL-3

ABSTRACT TL-3 is a protease inhibitor developed using the feline immunodeficiency virus protease as a model. It has been shown to efficiently inhibit replication of human, simian, and feline immunodeficiency viruses and therefore has broad-based activity. We now demonstrate that TL-3 efficiently inhibits the replication of 6 of 12 isolates with confirmed resistance mutations to known protease inhibitors. To dissect the spectrum of molecular changes in protease and viral properties associated with resistance to TL-3, a panel of chronological in vitro escape variants was generated. We have virologically and biochemically characterized mutants with one (V82A), three (M46I/F53L/V82A), or six (L24I/M46I/F53L/L63P/V77I/V82A) changes in the protease and structurally modeled the protease mutant containing six changes. Virus containing six changes was found to be 17-fold more resistant to TL-3 in cell culture than was wild-type virus but maintained similar in vitro replication kinetics compared to the wild-type virus. Analyses of enzyme activity of protease variants with one, three, and six changes indicated that these enzymes, compared to wild-type protease, retained 40, 47, and 61% activity, respectively. These results suggest that deficient protease enzymatic activity is sufficient for function, and the observed protease restoration might imply a selective advantage, at least in vitro, for increased protease activity.

[1]  B. Larder,et al.  Mutations in Retroviral Genes Associated with Drug Resistance , 1996 .

[2]  A. Kudo,et al.  A Novel Aqueous Process for Preparation of Crystal Form-Controlled and Highly Crystalline BiVO4 Powder from Layered Vanadates at Room Temperature and Its Photocatalytic and Photophysical Properties , 1999 .

[3]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[4]  D. Trono,et al.  Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import , 1996, Journal of virology.

[5]  Volker Brendel,et al.  Identification of Biased Amino Acid Substitution Patterns in Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Protease Inhibitors , 1999, Journal of Virology.

[6]  Brendan A. Larder,et al.  Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples , 2000, AIDS.

[7]  Arthur J. Olson,et al.  Alteration of Substrate and Inhibitor Specificity of Feline Immunodeficiency Virus Protease , 2000, Journal of Virology.

[8]  B. Torbett,et al.  Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Falloon,et al.  Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites , 1997, Journal of virology.

[10]  F. Mammano,et al.  Effects of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors on Reverse Transcriptase Processing, Activity, and Drug Sensitivity , 1999, Journal of Virology.

[11]  B. Efron,et al.  Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. , 1999, The Journal of infectious diseases.

[12]  John M. Leonard,et al.  Genotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy , 1998, Journal of Virology.

[13]  A. Wlodawer,et al.  Structural studies of FIV and HIV‐1 proteases complexed with an efficient inhibitor of FIV protease , 2000, Proteins.

[14]  D. Lamarre,et al.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors , 1997, Journal of virology.

[15]  D. Lamarre,et al.  Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors , 1996, Journal of virology.

[16]  L. Babe,et al.  Defining the Level of Human Immunodeficiency Virus Type 1 ( HIV-1 ) Protease Activity Required for HIV-1 Particle Maturation and Infectivity , 1995 .

[17]  D Norbeck,et al.  Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor , 1994, Journal of virology.

[18]  O. Kirk,et al.  Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. , 1999, AIDS.

[19]  O. Turriziani,et al.  Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. , 1994, Acta virologica.

[20]  A. Telenti,et al.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.

[21]  Arthur J. Olson,et al.  Development of a New Type of Protease Inhibitors, Efficacious against FIV and HIV Variants , 1999 .

[22]  D. Ho,et al.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.

[23]  F. Mammano,et al.  Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.

[24]  C. Sabin,et al.  Virological response to protease inhibitor therapy in an HIV clinic cohort. , 1999, AIDS.

[25]  R. Haubrich,et al.  Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[26]  Alexander Wlodawer,et al.  Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus , 1995, Nature Structural Biology.

[27]  D E Mosier,et al.  Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. , 1993, Science.

[28]  T. Lee,et al.  ネコ免疫不全ウイルス(FIV)プロテアーゼのS3およびS3′サブサイト特異性の分析 in vitroおよびex vivoで,FIV,SIVおよびHIVに効果のある広範囲プロテアーゼ阻害剤の研究 , 1998 .

[29]  H. B. Schock,et al.  Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical Trials , 1996, The Journal of Biological Chemistry.

[30]  F. Mammano,et al.  Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease andgag Coevolution in Protease Inhibitor-Treated Patients , 1998, Journal of Virology.

[31]  Steven C. Johnson,et al.  Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. , 1998, The Journal of infectious diseases.

[32]  E. Rosenberg,et al.  Reduced antiretroviral drug susceptibility among patients with primary HIV infection. , 1999, JAMA.

[33]  M. Ott,et al.  In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. , 1996, The Journal of infectious diseases.

[34]  A. Telenti,et al.  Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. , 2000, AIDS research and human retroviruses.

[35]  G. Marshall,et al.  A simple, continuous fluorometric assay for HIV protease. , 2009, International journal of peptide and protein research.

[36]  H. B. Schock,et al.  Three-dimensional Structure of a Mutant HIV-1 Protease Displaying Cross-resistance to All Protease Inhibitors in Clinical Trials (*) , 1995, The Journal of Biological Chemistry.

[37]  Zachary Q. Beck,et al.  Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development. , 2000, Virology.

[38]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[39]  I B Duncan,et al.  Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. , 1995, Virology.

[40]  J. Konvalinka,et al.  An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity , 1995, Journal of virology.

[41]  J. Barrish,et al.  Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor , 1995, Journal of virology.

[42]  J. Mascola,et al.  Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel , 2000, AIDS.

[43]  E A Emini,et al.  Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.

[44]  J. Martinez-Picado,et al.  Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.